The present invention relates to the use of compounds of a cannabinoid nature for inhibiting viability with increasing doses of myeloma cell lines. Furthermore, these same compounds have been shown not to affect CD34+ cells (normal hematopoietic progenitors) in terms of viability and proliferation. Therefore, this invention paves the way for the use of compounds of a cannabinoid nature as a promising therapy against multiple myeloma and related diseases.